Vistagen Therapeutics Inc (VTGN) Holdings Increased by Ladenburg Thalmann Financial Services Inc.

Ladenburg Thalmann Financial Services Inc. grew its holdings in shares of Vistagen Therapeutics Inc (NASDAQ:VTGN) by 131.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 104,414 shares of the company’s stock after acquiring an additional 59,338 shares during the period. Ladenburg Thalmann Financial Services Inc.’s holdings in Vistagen Therapeutics were worth $116,000 as of its most recent SEC filing.

Separately, Sphera Funds Management LTD. grew its stake in shares of Vistagen Therapeutics by 17.8% in the 4th quarter. Sphera Funds Management LTD. now owns 1,247,251 shares of the company’s stock valued at $1,384,000 after buying an additional 188,865 shares during the period. 20.85% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Several analysts have recently commented on VTGN shares. Chardan Capital reduced their target price on Vistagen Therapeutics from $30.00 to $22.00 and set a “buy” rating for the company in a research note on Thursday, February 8th. Zacks Investment Research restated a “buy” rating and issued a $1.00 target price on shares of Vistagen Therapeutics in a research note on Saturday, April 7th.

Shares of VTGN opened at $1.19 on Tuesday. The stock has a market capitalization of $26.11, a PE ratio of -0.77 and a beta of -0.09. Vistagen Therapeutics Inc has a one year low of $0.69 and a one year high of $2.65.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Monday, February 12th. The company reported ($0.24) earnings per share for the quarter. analysts anticipate that Vistagen Therapeutics Inc will post -1.89 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Want to see what other hedge funds are holding VTGN? Visit to get the latest 13F filings and insider trades for Vistagen Therapeutics Inc (NASDAQ:VTGN).

Institutional Ownership by Quarter for Vistagen Therapeutics (NASDAQ:VTGN)

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply